Monika Keževičiūtė

Ms. Monika Keževičiūtė

Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Santariskiu g. 2, LT-08661 Vilnius, Lithuania; monika.kezeviciute@santa.lt
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
MKMonika Keževičiūtė
Monika Keževičiūtė
GMGermanas Marinskis
Germanas Marinskis
DSDiana Sudaviciene
Diana Sudaviciene
BJBarysienė Jūratė
Barysienė Jūratė
NBNeringa Bileišienė
Neringa Bileišienė
GRGediminas Račkauskas
Gediminas Račkauskas
Atrial fibrillation (AF) is the most common supraventricular arrhythmia, affecting 2–3% of the adult population, with an increasing prevalence due to demographic shifts; however, detection methods have also improved. This rhythm disorder is associated with significant morbidity, manifesting through symptoms that worsen the quality of life, as well as with adverse outcomes and increased mortality. The substantial AF burden on the healthcare system necessitates the development of effective and durable treatment strategies. While pharmacological management represents the first-line approach for AF, the limitations associated with this approach, including side effects and insufficient efficacy, have promoted the evolution of catheter ablation techniques that isolate pulmonary veins (PVs) and, thus, disrupt arrhythmia-causing impulses from the atria. Currently, three energy sources have gained U.S. Food and Drug Administration (FDA) and European regulatory approval (The Conformité Européene (CE) mark certification) for catheter ablation: radiofrequency ablation (RFA), cryoballoon ablation (CBA), and, more recently, pulsed-field ablation (PFA). RFA has subsequently become an effective treatment, demonstrating superior outcomes in randomized controlled trials compared to antiarrhythmic drug therapy. CBA has also proven to be a safe and effective alternative, particularly for patients with symptomatic paroxysmal AF, showing comparable efficacy to RFA and similar rates of complications. Meanwhile, PFA is emerging as a promising technique, offering non-inferior efficacy to conventional thermal methods while potentially minimizing the thermal damage to adjacent tissues associated with RFA and CBA. Despite higher equipment costs, the advantages of PFA in reducing complications highlight its potential role in AF management. However, considering the novelty of PFA, no data currently exist comparing this strategy with thermal techniques. Therefore, further research is needed to improve the management of AF and patient outcomes to reduce healthcare burdens.

25 June 2025 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
GRGediminas Rackauskas
Gediminas Rackauskas
RKRičardas Kundelis
Ričardas Kundelis
AAAudrius Aidietis
Audrius Aidietis
BJBarysienė Jūratė
Barysienė Jūratė
DSDiana Sudaviciene
Diana Sudaviciene
PJPeter Karl Jacobsen
Peter Karl Jacobsen
Robotic magnetic navigation (RMN) has demonstrated clinical utility in treating arrhythmia patients by providing direct distal-tip control of an ablation catheter, enhancing catheter precision, safety, and stability with an atraumatic catheter design. We aimed to assess the first in-human efficacy and safety of the new RMN-guided MAGiCTM radiofrequency ablation catheter. This prospective, multicenter single-arm, unblinded study enrolled 67 patients with arrhythmias that met EHRA guidelines for catheter ablation. All patients were treated for their index arrhythmia with the MAGiC RMN catheter. All other devices used in the procedures were approved for treatment including a RMN System (Genesis/Niobe®) used to navigate the MAGiC catheter. Acute procedural success and adverse events were assessed for all patients through discharge from the hospital in the days following the procedure. Sixty-seven patients were treated as follows: 25 cases of atrioventricular nodal reentrant tachycardia, 19 of premature ventricular contractions, 8 of Wolf-Parkinson-White (WPW) syndrome, 8 of atrial fibrillation, 3 of atrial flutter, and 4 of ventricular tachycardia. Acute procedural success was 94%. There was one cardiac tamponade due to perforation of the right ventricular outflow tract during ablation. Otherwise, no adverse events were observed. The results of this study demonstrate good acute efficacy and safety of the MAGiC RMN ablation catheter independent of underlying arrhythmias. Contact force and stability with MAGiC seem improved compared to previous catheters available with RMN, and therefore radiofrequency energy delivery needs careful attention, especially in thin areas of the myocardium. Additional long-term data are needed.

16 July 2021 in Medicina
Verified
Journal Article
Open access
PDF file
NBNeringa Bileisiene
Neringa Bileisiene
BJBarysienė Jūratė
Barysienė Jūratė
VMVioleta Mikštienė
Violeta Mikštienė
EPEglė Preikšaitienė
Eglė Preikšaitienė
GMGermanas Marinskis
Germanas Marinskis
AAAudrius Aidietis
Audrius Aidietis
Congenital long QT syndrome (LQTS) is a hereditary ion channelopathy associated with ventricular arrhythmia and sudden cardiac death starting from young age due to prolonged cardiac repolarization, which is represented by QT interval changes in electrocardiogram (ECG). Mutations in human ether-à-go-go related gene (KCNH2 (7q36.1), formerly named hERG) are responsible for Long QT syndrome type 2 (LQT2). LQT2 is the second most common type of LQTS. A resuscitated 31-year-old male with the diagnosis of LQT2 and his family are described. Sequencing analysis of their genomic DNA was performed. Amino acid alteration p.(Ser631Pro) in KCNH2 gene was found. This variant had not been previously described in literature, and it was found in three nuclear family members with different clinical course of the disease. Better understanding of genetic alterations and genotype-phenotype correlations aids in risk stratification and more effective management of these patients, especially when employing a trigger-specific approach to risk-assessment and individually tailored therapy.

24 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MKMonika Keževičiūtė
Monika Keževičiūtė
NBNeringa Bileisiene
Neringa Bileisiene
VMVioleta Mikštienė
Violeta Mikštienė
GMGermanas Marinskis
Germanas Marinskis
BJBarysienė Jūratė
Barysienė Jūratė
Multifocal ectopic Purkinje-related premature contractions (MEPPC) syndrome is a recently recognized rare form of arrhythmia involving the entire His–Purkinje system and often coinciding with dilated cardiomyopathy (DCM). Certain variants in the SCN5A gene may be linked to MEPPC syndrome. We present a case of a 32-year-old Caucasian female who exhibited a high burden of premature ventricular contractions (PVCs) and non-sustained episodes of ventricular tachycardia (NSVT) with an alternating QRS pattern, and who was resistant to traditional medical therapy and radiofrequency catheter ablation (RFCA), necessitating implantation of a cardioverter-defibrillator (ICD). A positive family history (father’s death at the age of 40 years) and the rapid deterioration of left ventricular function parameters echocardiographically during recurrent arrhythmic episodes raised concern about a potentially complex disease scenario. Genetic testing revealed a heterozygous variant of the SCN5A gene, c.2440C>T, p.(Arg814Trp), confirming the diagnosis of MEPPC syndrome. Treatment with a combination of class I antiarrhythmic drugs, flecainide and mexiletine, concomitant with beta blockers, led to symptomatic improvement, a reduction of PVCs (from 66 491 (44%) to 858 (1%)), and the restoration of left ventricular function (LV EF from 44% to 53%). A lack of defined diagnostic criteria hampers timely diagnosis, leading to ineffective interventions and delayed initiation of treatment with antiarrhythmic drugs. MEPPC patients remain at significant risk for severe heart failure and sudden cardiac death. Our clinical case report underscores the importance of accurate and timely diagnosis, which allows effective treatment with a combination of antiarrhythmic drugs and mitigates the risk associated with MEPPC syndrome.

16 November 2023 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
MKMonika Keževičiūtė
Monika Keževičiūtė
DZDiana Zakarkaite
Diana Zakarkaite
VJVilius Janusauskas
Vilius Janusauskas
SGSigita Glaveckaitė
Sigita Glaveckaitė
A 77-year-old woman underwent a surgical aortic valve replacement (SAVR) with St. Jude Medical Biocor 21 mm prosthesis (P) due to symptomatic severe aortic stenosis (peak velocity 4.6 m/s, mean gradient 54 mmHg, aortic valve area 0.92 cm2). During a routine follow-up visit after 6 years, the patient had no complaints, and all her vitals were normal. Routine transthoracic echocardiography revealed para-aortic masses of unknown aetiology (Panel A, asterisk). Measured effective orifice area (EOA) matched normal reference value of the implanted prosthesis; however, moderate patient-prosthetic mismatch (PPM) was confirmed (indexed EOA 0.8 cm2/m2). Initially, para-aortic abscesses, explaining increased trans-prosthetic gradients (peak velocity 4.6 m/s, mean gradient 47 mmHg) by ongoing active infectious process, were suspected. However, laboratory tests demonstrated no significant elevation of inflammatory markers. Differential diagnosis included aortic dissection. To rule out acute aortic syndromes, a computed tomography angiography was performed. No disruption of aortic wall was apparent, and para-aortic masses were confirmed (Panel B, asterisks). Transoesophageal echocardiography was consistent with normal prosthesis function and the same high trans-prosthetic gradients related to PPM. In addition, homogenous, normoechogenic, encapsulated semi-lunar para-aortic masses (15 mm thin) were observed anteriorly and medially to the aortic root (Panels C and D, asterisks). Based on these findings, the Multidisciplinary Valvular Team concluded that para-aortic masses are the conglomeration of unresorbed haemostatic fabrics (Johnson & Johnson NU-KNIT Absorbable Haemostats), used during SAVR. No urgent interventions were recommended at a time, and the patient was scheduled for regular follow-ups considering the possible necessity of TAVR in the future.